Shamika Gune
About
In The Last Decade
Shamika Gune
33 papers receiving 488 citations
Peers
Comparison fields: 5 of 37
- Ophthalmology 472
- Radiology, Nuclear Medicine and Imaging 433
- Molecular Biology 72
- Public Health, Environmental and Occupational Health 20
- Pharmaceutical Science 15
Countries citing papers authored by Shamika Gune
This map shows the geographic impact of Shamika Gune's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shamika Gune with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shamika Gune more than expected).
Fields of papers citing papers by Shamika Gune
This network shows the impact of papers produced by Shamika Gune. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shamika Gune. The network helps show where Shamika Gune may publish in the future.
Co-authorship network of co-authors of Shamika Gune
This figure shows the co-authorship network connecting the top 25 collaborators of Shamika Gune. A scholar is included among the top collaborators of Shamika Gune based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shamika Gune. Shamika Gune is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 10 | |
| 5 | 2 | |
| 6 | 8 | |
| 7 | 9 | |
| 8 | Pharmacokinetic profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Archway trial | 5 |
| 9 | 23 | |
| 10 | Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD: End of Study Results | 1 |
| 11 | Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial | 3 |
| 12 | Optimization of the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure in the Ladder Phase 2 Trial | 1 |
| 13 | 5 | |
| 14 | 56 | |
| 15 | 45 | |
| 16 | Relationship between sub retinal fluid (SRF) and vision outcomes in eyes with neovascular age-related macular degeneration (nAMD) in the HARBOR trial | 2 |
| 17 | 39 | |
| 18 | 36 | |
| 19 | A longitudinal SD-OCT analysis of macular atrophy in the HARBOR trial | 2 |
| 20 | Ranibizumab induces regression of diabetic retinopathy (DR) in more than three-quarters of patients with high-risk non-proliferative diabetic retinopathy (NPDR) independent of retinal nonperfusion | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.